Index RUT
P/E -
EPS (ttm) -0.97
Insider Own 7.85%
Shs Outstand 48.09M
Perf Week -1.00%
Market Cap 427.18M
Forward P/E -
EPS next Y -0.33
Insider Trans -0.20%
Shs Float 44.38M
Perf Month -5.64%
Income -55.19M
PEG -
EPS next Q -0.25
Inst Own 101.64%
Short Float 18.94%
Perf Quarter -22.19%
Sales 57.42M
P/S 7.44
EPS this Y 38.25%
Inst Trans -0.40%
Short Ratio 23.08
Perf Half Y -1.66%
Book/sh 4.43
P/B 2.00
EPS next Y 47.10%
ROA -11.16%
Short Interest 8.40M
Perf Year -16.16%
Cash/sh 2.13
P/C 4.17
EPS next 5Y -
ROE -16.86%
52W Range 8.21 - 12.03
Perf YTD -21.09%
Dividend Est. -
P/FCF -
EPS past 5Y 24.22%
ROI -21.37%
52W High -26.27%
Beta 0.36
Dividend TTM -
Quick Ratio 5.39
Sales past 5Y 0.23%
Gross Margin 89.46%
52W Low 8.04%
ATR (14) 0.32
Dividend Ex-Date -
Current Ratio 5.39
EPS Y/Y TTM 72.89%
Oper. Margin -92.81%
RSI (14) 48.86
Volatility 2.97% 3.62%
Employees 99
Debt/Eq 0.23
Sales Y/Y TTM 11.84%
Profit Margin -96.12%
Recom 2.00
Target Price 14.00
Option/Short Yes / Yes
LT Debt/Eq 0.21
EPS Q/Q -11.96%
Payout -
Rel Volume 0.48
Prev Close 9.01
Sales Surprise -0.06%
EPS Surprise -15.25%
Sales Q/Q 19.91%
Earnings Feb 26 AMC
Avg Volume 364.11K
Price 8.87
SMA20 0.31%
SMA50 -1.80%
SMA200 -8.80%
Trades
Volume 136,491
Change -1.55%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-08-24 Downgrade
Evercore ISI
Outperform → In-line
May-23-22 Initiated
SVB Leerink
Outperform
$12
Nov-05-21 Upgrade
JP Morgan
Underweight → Neutral
$12
Sep-15-21 Downgrade
JP Morgan
Overweight → Underweight
$7
Aug-25-21 Downgrade
Morgan Stanley
Overweight → Underweight
$27 → $14
Aug-24-21 Downgrade
Cowen
Outperform → Market Perform
$42 → $14
Oct-14-20 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$32
Jul-07-20 Initiated
JP Morgan
Overweight
$29
Jun-15-20 Initiated
Morgan Stanley
Equal-Weight
$30
May-13-20 Initiated
Cowen
Outperform
$42
Jan-08-20 Reiterated
H.C. Wainwright
Buy
$25 → $30
Nov-06-19 Upgrade
Robert W. Baird
Underperform → Neutral
$22 → $18
Oct-29-19 Initiated
H.C. Wainwright
Buy
$25
Mar-29-18 Resumed
Piper Jaffray
Overweight
$45
Aug-17-17 Initiated
Evercore ISI
Outperform
$45
Jun-16-17 Initiated
Cantor Fitzgerald
Overweight
$55
May-11-17 Reiterated
Needham
Buy
$40 → $45
Dec-21-16 Initiated
Needham
Buy
$40
Nov-03-16 Initiated
Piper Jaffray
Overweight
Oct-12-16 Downgrade
Robert W. Baird
Neutral → Underperform
$19 → $24
Show Previous Ratings
Mar-27-24 11:30AM
Mar-12-24 03:59PM
Feb-28-24 10:35AM
Feb-27-24 11:47AM
Feb-26-24 05:25PM
04:39PM
Loading…
04:39PM
(Associated Press Finance)
04:05PM
Feb-22-24 06:00AM
Feb-14-24 06:00AM
Jan-12-24 09:35AM
Jan-05-24 06:00AM
Dec-24-23 01:08PM
Dec-21-23 05:00PM
Dec-18-23 06:00AM
Dec-07-23 11:30AM
09:14AM
Loading…
Nov-22-23 09:14AM
Nov-16-23 06:00AM
Nov-15-23 06:00AM
Nov-13-23 08:00AM
Nov-08-23 02:10PM
11:35AM
Nov-07-23 06:09PM
(Associated Press Finance)
04:28PM
Oct-19-23 06:00AM
Sep-06-23 11:30AM
Aug-31-23 05:55PM
Aug-29-23 06:00AM
Aug-28-23 06:05AM
Aug-09-23 06:25AM
Aug-08-23 09:54AM
05:25PM
Loading…
Aug-07-23 05:25PM
04:25PM
(Associated Press Finance)
04:05PM
Aug-01-23 10:00AM
Jul-24-23 06:00AM
Jul-03-23 09:00AM
Jun-08-23 11:14AM
Jun-07-23 11:30AM
May-18-23 01:50PM
May-11-23 03:41PM
10:45AM
May-10-23 11:34AM
06:03AM
May-09-23 06:00PM
09:24AM
May-08-23 05:55PM
04:05PM
May-04-23 10:00AM
May-01-23 10:01AM
Apr-24-23 06:00AM
Apr-19-23 02:42PM
Apr-17-23 07:47AM
Apr-14-23 04:23AM
Apr-11-23 04:05PM
Apr-10-23 06:00AM
Mar-31-23 12:41PM
11:30AM
Mar-30-23 05:22PM
11:30AM
Mar-29-23 11:30AM
Mar-10-23 06:56AM
Mar-08-23 02:50PM
Mar-02-23 06:00AM
Feb-28-23 02:17PM
01:33PM
Feb-27-23 06:15PM
04:05PM
11:26AM
09:00AM
Feb-23-23 07:46AM
Feb-21-23 06:00AM
Feb-16-23 10:01AM
Feb-15-23 10:00AM
Feb-09-23 06:00AM
Jan-09-23 06:00AM
Dec-25-22 09:39AM
Dec-07-22 11:30AM
Nov-22-22 04:15PM
Nov-18-22 06:00AM
Nov-11-22 08:20AM
Nov-08-22 08:34AM
Nov-07-22 05:45PM
04:05PM
Nov-02-22 04:30PM
Oct-31-22 06:00AM
Oct-27-22 10:02AM
Oct-26-22 10:02AM
Oct-25-22 06:00AM
Sep-28-22 06:00AM
Sep-20-22 09:36AM
Sep-19-22 02:28PM
07:22AM
06:00AM
Sep-08-22 11:30AM
Sep-06-22 06:00AM
Aug-14-22 08:06AM
Aug-05-22 11:53AM
Aug-04-22 07:25PM
04:05PM
Jul-28-22 06:00AM
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Feb 22 '24 Sale 8.71 1,254 10,922 311,733 Feb 22 08:04 PM Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Nov 21 '23 Sale 10.29 1,378 14,180 331,206 Nov 22 06:07 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Nov 14 '23 Sale 10.22 2,482 25,366 346,839 Nov 16 06:16 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Oct 16 '23 Sale 9.03 2,482 22,412 334,321 Oct 18 06:54 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Sep 14 '23 Sale 9.89 2,482 24,547 336,803 Sep 18 06:08 PM Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Aug 22 '23 Sale 9.47 1,807 17,112 340,566 Aug 24 06:05 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Aug 11 '23 Sale 9.99 2,322 23,197 349,746 Aug 15 06:09 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Jul 14 '23 Sale 9.84 2,322 22,848 352,068 Jul 18 06:14 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Jun 14 '23 Sale 10.69 2,322 24,822 354,390 Jun 16 06:14 PM Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Jun 08 '23 Sale 11.13 1,790 19,923 352,833 Jun 12 06:08 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT May 15 '23 Sale 11.26 2,322 26,146 367,172 May 17 06:17 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Apr 14 '23 Sale 11.88 2,323 27,597 369,494 Apr 18 05:49 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite